Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Study shows ability of Prostascint to predict prostate cancer deaths:

This article was originally published in Clinica

Executive Summary

In what could boost the profile of Prostascint, eight-year outcomes data from a 341-patient study has found that the imaging agent can predict the likelihood of prostate cancer-related deaths. The study, which was presented at last month's American Urological association, in Anaheim, California, found that prostate cancer-specific deaths were 10 times higher in patients that showed central abdominal uptake (CAU) of the agent, which is indicative of metastatic activity. Manufacturers of the agent, Princeton, New Jersey-based Cytogen, commented that the data "reinforces the value of information obtained from Prostascint scans to assist in selection of appropriate therapy". In January of this year, Prostascint was included in the US National Comprehensive Cancer Network (NCCN) clinical practise guidelines for recurrent prostate cancer.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT048467

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel